ArticleJournal for immunotherapy of cancer2022

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Sophia Stock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.